Hormone receptors (ER and PR) and human epidermal growth factor receptor-2 (HER-2) are the most relevant clinical biomarkers that are widely used in stratifying breast cancer cases management and heterogeneity of the carcinoma breast and unpredictable behavior in many cases necessitate the exploration of prognostic use of other markers. Here, ERBB2 is linked to breast carcinoma.